Carmell CORP

Longevity Health Holdings announces a settlement with Puritan Partners, resolving litigation that had previously constrained its access to capital and strategic opportunities.

Kathryn Gregory has resigned from the Board of Directors of Longevity Health Holdings, Inc., effective June 1, 2026.

Longevity Health Holdings, Inc. announced a strategic private placement and the appointment of Janakiram Ajjarapu as its new Chairman and Chief Executive Officer, signaling a shift towards an acquisition-focused growth strategy.

Longevity Health Holdings, Inc. announced the termination of its merger agreement with True Health Inc. after the transaction was not consummated by the November 30, 2025 deadline.

Longevity Health Holdings, Inc. amended its merger agreement with True Health Inc. to adjust the calculation of merger and earnout shares based on a market price floor.

Longevity Health Holdings, Inc. has been delisted from the Nasdaq Capital Market and its securities have commenced trading on the OTC marketplace due to a listing rule deficiency.

Longevity Health Holdings, Inc. filed its Q2 2026 10-Q, revealing a significant net loss, declining sales, and substantial doubt about its ability to continue as a going concern.

Longevity Health Holdings, Inc. reported a reduced net loss for Q3 2025, driven by the Elevai acquisition, but faces Nasdaq delisting and significant going concern doubts while pursuing a merger with THPlasma.

Longevity Health Holdings, Inc. reported significant revenue growth in Q2 2025, driven by the Elevai acquisition, while announcing a definitive merger agreement with True Health Inc. and addressing ongoing financial challenges.

Longevity Health Holdings announces its Q1 2025 financial results, highlighting the Elevai Skincare acquisition and ongoing efforts to regain Nasdaq compliance amidst a proposed merger with 20/20 Biolabs.

Carmell Corporation's Q3 2024 results show a strategic shift towards cosmetic skincare, reduced R&D spending, and ongoing efforts to manage liquidity amidst a net loss.

Carmell Corporation's Q2 2024 report highlights a strategic shift towards cosmetic skincare and haircare, alongside the divestiture of AxoBio.

Longevity Health Holdings, Inc. filed an amended annual report revealing substantial net losses, negative working capital, and ongoing Nasdaq delisting challenges, despite recent capital raises and a strategic pivot to cosmetic bio-aesthetics.

Longevity Health Holdings, Inc. reports its 2024 financial results, highlighting a strategic shift towards bio-aesthetics and addressing concerns about its ability to continue as a going concern.

Carmell Corporation has filed an amendment to its annual report to include information about directors, executive compensation, and other corporate governance matters, as well as updated certifications from its CEO and CFO.

Carmell Corporation's 10-K filing details the company's registered securities, including common stock and warrants, and outlines key corporate governance provisions.

Ajjarapu J. Ram, a Director and CEO of Longevity Health Holdings, Inc., acquired 689,656 shares of common stock at $0.29 per share.

Kendra Bracken-Ferguson, CEO of Carmell Corp, reports acquisition of stock options.

Bryan J. Cassaday, CFO of Carmell Corp, reports the acquisition of stock options and the disposal of common stock.

Director Gilles Spenlehauer reports acquisition of stock options and indirect ownership of common stock through Carmell Insiders LLC.

Director Patrick Sturgeon reports changes in beneficial ownership of Carmell Corp stock, including option grants and shares held through Carmell Insiders LLC.

Director Richard A. Upton reports changes in beneficial ownership of Carmell Corp stock and stock options.

Carmell Corporation has filed a definitive proxy statement with the SEC regarding an upcoming special meeting.

Carmell Corporation is holding a special meeting to seek stockholder approval for a warrant exercise proposal and a reverse stock split to comply with Nasdaq listing rules.

Carmell Corporation has filed a definitive proxy statement with the Securities and Exchange Commission.

Carmell Corporation will hold its 2024 Annual Meeting of Stockholders virtually on July 12, 2024, to vote on the election of a director and the ratification of its independent accounting firm.

Carmell Corporation has filed an amendment to its registration statement for the resale of up to 1,331,452 shares of common stock by selling stockholders following a private placement.

Carmell Corporation files an S-1 registration statement for the resale of 1,331,452 shares of common stock by selling stockholders following a recent private placement.

Longevity Health Holdings announces significant leadership changes with Janakiram Ajjarapu appointed CEO and Chairman, following a substantial stock acquisition by International Capital Partners LLC.

Newlin Investment Company 1, LLC and William R. Newlin have filed an amended Schedule 13G, reporting a 4.2% beneficial ownership stake in Carmell Corp's common stock.

Newlin Investment Company 1, LLC and William R. Newlin have filed an amended Schedule 13G, reaffirming their beneficial ownership of 6.1% of Carmell Corp's common stock as of December 31, 2024.